Clinical Trial: DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06988475) titled 'DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations' on May 16.

Brief Summary: This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

Capmatinib works in lung cancer patients with a particular mutation in their cancer known as a METex14 skipping mutation.

Investigators now wish to find out if it will be useful in treating patient...